In summary, the MAPK, NF-κB, P53, and PI3K-Akt pathways were revealed to be associated with the patients of MM or DLBCL with COVID-19 infection and could, therefore, be studied in future research to reveal novel targets for COVID-19 therapy. Here, NFKB1 is linked to Miyoshi myopathy.